Shares of Aravive Inc (NASDAQ:ARAV) have received a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus target price of $30.00 for the company and are expecting that the company will post ($0.54) EPS for the current quarter, according to Zacks. Zacks has also given Aravive an industry rank of 58 out of 255 based on the ratings given to related companies.
ARAV has been the subject of several research analyst reports. Piper Jaffray Companies restated an “overweight” rating and set a $31.00 price target (down from $36.00) on shares of Aravive in a research note on Tuesday. Robert W. Baird upgraded Aravive from a “neutral” rating to an “outperform” rating in a research note on Monday. ValuEngine lowered Aravive from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Wedbush upped their price target on Aravive from $12.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 20th. Finally, HC Wainwright restated a “buy” rating and set a $31.00 price target (up from $18.00) on shares of Aravive in a research note on Wednesday, November 20th.
Aravive (NASDAQ:ARAV) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.04). Equities research analysts predict that Aravive will post -1.78 earnings per share for the current fiscal year.
In other Aravive news, CEO Jay Shepard sold 4,004 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $6.82, for a total transaction of $27,307.28. Also, Director Srinivas Akkaraju acquired 133,333 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were bought at an average price of $11.30 per share, with a total value of $1,506,662.90. Corporate insiders own 39.80% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Artal Group S.A. increased its position in shares of Aravive by 20.0% during the 2nd quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock worth $1,845,000 after purchasing an additional 51,197 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Aravive by 13.8% during the 2nd quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock worth $890,000 after acquiring an additional 18,017 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Aravive by 5.8% during the 2nd quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock worth $1,044,000 after acquiring an additional 9,544 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Aravive by 4.7% in the 2nd quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock valued at $955,000 after purchasing an additional 7,200 shares during the period. Hedge funds and other institutional investors own 30.85% of the company’s stock.
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Read More: Trading on Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.